Hatteras Venture Partners closes on additional $50.1M for new fund; target is $250M

DURHAM – Hatteras Venture Partners, one of the largest and most active venture capital funds based in North Carolina, has closed on additional $50.1 million of a new fund, HVP VI, according to a recent securities filing.

That’s in addition to $86.3 million raised in April of last year, bringing its total raised to date to $137.3 million.

Sixty four investors contributed to the round, the filing noted. The target is $250 million.

“The pace and quality of our deal flow has grown tremendously during the past several years,” said Clay Thorp, co-founder and General Partner of Hatteras, when the company kicked off the fund.

“With HVP VI, we will continue to partner with innovative, driven entrepreneurs to launch and build world-class health care companies, many of which will be based upon leading-edge research stemming from the renowned academic centers in the southeastern U.S. In addition, we will continue to leverage our expanding national network to co-invest in promising companies in other regions.”

Hatteras investments include G1 Therapeutics, PhaseBio, Kymera, Rodin, Elligo Health Research and Ribometrix.

The firm has more than $500 million under management.